Business Context and Reporting Period
This Form 8-K is a current report filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on September 17, 2015, covering events occurring on September 14, 2015. The filing discloses a significant executive appointment and related press release under Regulation FD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of Dr. Richard Bender, MD, FACP, as the Company's new Chief Medical Officer (CMO), effective September 14, 2015. Dr. Bender reports directly to Samuel D. Riccitelli, President and CEO.
Management Commentary and Outlook
- Executive Background: Dr. Bender brings over 30 years of experience in clinical oncology, hematology, and medical diagnostics.
- Previous Roles: He previously served as CMO and VP at Agendia, Inc., Medical Director at Quest Diagnostics, and held senior roles at Johnson & Johnson and the National Cancer Institute.
- Expertise: His career includes authoring over 75 peer-reviewed articles and managing regulatory submissions for hematology/oncology tests.
- Regulatory Note: The press release and associated information are not deemed filed for Section 18 liability purposes under the Exchange Act.
Investor Verification Checklist
- Verify the effective date of Dr. Bender's appointment (September 14, 2015).
- Confirm the reporting line to President and CEO Samuel D. Riccitelli.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the CMO role.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.